Doctor Explains Retatrutide: The Most Powerful GLP-1 Weight Loss Drug Yet
A urologist and creator walks through how retatrutide's three-receptor design differs from semaglutide and tirzepatide, with phase 2 trial numbers, side effects and expected timing.
With Dr. Alex Tatem (board-certified, fellowship-trained urologist)
Key moments
Tap a moment to play the video from there.
- 0:00Intro and five-point planTatem introduces himself as a urologist and lists the five questions the video will cover, from GLP-1 basics to market timing.
- 2:12What GLP-1 agonists doHe describes GLP-1 as slowing gastric emptying, stimulating insulin release and reducing food reward, then traces semaglutide in 2017 and tirzepatide in 2022.
- 4:24Three receptors explainedTatem says retatrutide targets GLP-1, GIP and glucagon, and describes GIP as amplifying GLP-1's effects on insulin and appetite.
- 5:35Why the glucagon receptor mattersHe argues glucagon activation raises energy expenditure and fat oxidation without runaway blood sugar when paired with the other two receptors. He mentions a fatty liver finding at high doses.
- 7:51Phase 2 weight loss resultsTatem reads out 48-week figures of 22.8% and 24.2% mean weight change and compares them with STEP 1 and SURMOUNT-1 numbers.
- 9:30Blood sugar and diabetes dataHe cites an A1C reduction of two points at 24 weeks on 12 mg versus 1.4 with dulaglutide, plus 16.8 to 16.9% weight loss at 36 weeks in people with diabetes.
- 10:16Side effects and safety signalsTatem lists GI complaints, a dose-dependent heart rate rise and low rates of arrhythmia, biliary disorders and pancreatitis from the phase 2 trial.
- 12:45Phase 3 timeline and approvalHe says TRIUMPH obesity trials are set for primary completion in May 2026, making 2027 the best-case US approval, with a head-to-head against tirzepatide under way.
- 13:42Gray market warningTatem says he cannot recommend buying retatrutide from unofficial suppliers, citing inconsistent dosing and possible contamination.
What the video says
Dr. Alex Tatem, a urologist who focuses on men's health, gives a structured overview of retatrutide in five parts: a refresher on GLP-1 drugs, what sets retatrutide apart, how its trial results compare, its side effects, and when it might reach the market. The video is conversational and full of pop-culture asides, but the pharmacology and trial figures are laid out in order.
Tatem starts by describing the GLP-1 hormone and what it does: it slows stomach emptying, stimulates insulin release and dampens food reward. He then places semaglutide, which acts on GLP-1 only, and tirzepatide, which adds the GIP receptor, as the earlier steps. Retatrutide, he says, is the first triple agonist, adding the glucagon receptor. He explains that glucagon signalling nudges up energy expenditure and fat oxidation while the other two receptors keep blood sugar in check, and he gives a half-life of about 6 to 7 days, which supports weekly injections.
The comparison section relies on figures Tatem reads out from a phase 2 obesity trial in the New England Journal of Medicine, reporting mean weight changes of 22.8% on 8 mg and 24.2% on 12 mg over 48 weeks. He sets these against the STEP 1 semaglutide result of 14.9% at 68 weeks and the SURMOUNT-1 tirzepatide results of up to 20.9% at 72 weeks. He also cites an A1C drop of two points at 24 weeks on 12 mg, and notes that a phase 3 head-to-head against tirzepatide is ongoing.
On safety, Tatem reports mostly GI side effects tied to dose increases, a dose-dependent rise in heart rate, and low rates of arrhythmia, biliary events and pancreatitis. He expects phase 3 obesity data around May 2026 and says the best case for US approval is 2027. He advises against buying from unregulated suppliers, citing inconsistent dosing and contaminants. He presents all of this as his own reading of the data, not as personal medical advice.
On each compound
Retatrutide4:24
Tatem describes it as a triple agonist of GLP-1, GIP and glucagon receptors, given weekly with a half-life of about 6 to 7 days. He cites phase 2 results of 22.8% to 24.2% mean weight change at 48 weeks, and says phase 3 trials are still running.
See how your DNA reads RetatrutideSemaglutide7:51
Tatem says semaglutide acts on the GLP-1 receptor only. He cites the STEP 1 result of 14.9% average body weight loss at 68 weeks on 2.4 mg and notes common GI events.
See how your DNA reads SemaglutideTirzepatide7:51
According to Tatem, tirzepatide adds GIP receptor activity to GLP-1, which he credits for its greater potency over semaglutide. He cites SURMOUNT-1 losses of 15%, 19.5% and 20.9% at 5, 10 and 15 mg over 72 weeks.
See how your DNA reads TirzepatideWhat this video doesn’t settle
- The retatrutide, semaglutide and tirzepatide figures come from different trials with different lengths (48, 68 and 72 weeks), so the video does not establish a like-for-like comparison.
- Tatem notes no head-to-head obesity readout exists yet, so claims that retatrutide matches or beats tirzepatide remain provisional.
- The safety figures come from one phase 2 trial, and Tatem does not address long-term safety or the low-rate signals beyond saying they are being tracked in phase 3.
Questions this video answers
What makes retatrutide different from semaglutide and tirzepatide?
Tatem says semaglutide hits only the GLP-1 receptor and tirzepatide adds GIP, while retatrutide also activates the glucagon receptor. He argues this extra target raises energy expenditure and fat oxidation, which he links to the steeper early weight loss curve.
How much weight did people lose on retatrutide in the phase 2 trial?
Tatem reports mean weight changes of 22.8% on 8 mg and 24.2% on 12 mg over 48 weeks. He adds that by 24 weeks the top doses had reached 17.3 to 17.5%.
What side effects of retatrutide does Dr. Tatem mention?
He lists nausea in 27%, decreased appetite in 18%, diarrhea in 13%, vomiting in 10% and constipation in 9%, mostly when doses rose too quickly. He also mentions a dose-dependent heart rate increase and arrhythmias in 6% versus 3% on placebo.
When could retatrutide be approved?
Tatem says the main TRIUMPH obesity protocol is set for primary completion in May 2026, so the best case for US approval is 2027. He says a cardiovascular and renal outcomes study is estimated to finish in 2029.
Does Dr. Tatem recommend buying retatrutide from online suppliers?
No. He says he cannot recommend suppliers other than a legitimate or compounding pharmacy, citing inconsistent dosing and the risk of heavy metals and other contaminants.
Video by Dr. Alex Tatem on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
